| 저자(한글) |
Jung, Da Hoon,Kim, Mi-Sook,Cho, Chul Koo,Yoo, Hyung Jun,Jang, Won Il,Seo, Young Seok,Paik, Eun Kyung,Kim, Kum Bae,Han, Chul Ju,Kim, Sang Bum |
| 초록 |
Purpose: To report the results of stereotactic body radiotherapy (SBRT) for unresectable primary or recurrent cholangiocarcinoma. Materials and Methods: From January 2005 through August 2013, 58 patients with unresectable primary (n = 28) or recurrent (n = 30) cholangiocarcinoma treated by SBRT were retrospectively analyzed. The median prescribed dose was 45 Gy in 3 fractions (range, 15 to 60 Gy in 1-5 fractions). Patients were treated by SBRT only (n = 53) or EBRT + SBRT boost (n = 5). The median tumor volume was 40 mL (range, 5 to 1,287 mL). Results: The median follow-up duration was 10 months (range, 1 to 97 months). The 1-year, 2-year overall survival rates, and median survival were 45%, 20%, and 10 months, respectively. The median survival for primary group and recurrent group were 5 and 13 months, respectively. Local control rate at 1-year and 2-year were 85% and 72%, respectively. Disease progression-free survival rates at 1-year and 2-year were 26% and 23%, respectively. In univariate analysis, ECOG performance score (0-1 vs. 2-3), treatment volume ( ${ geq}50mL$ ), and pre-SBRT CEA level ( ${ geq}5ng/mL$ ) were significant in overall survival rate. In multivariate analysis, ECOG score (p = 0.037) and tumor volume (p = 0.030) were statistically significant. In the recurrent tumor group, patients with gt;12 months interval from surgery to recurrence showed statistically significant higher overall survival rate than those with ${ leq}12$ months (p = 0.026). Six patients (10%) experienced ${ geq}$ grade 3 complications. Conclusion: SBRT can be considered as an effective local modality for unresectable primary or recurrent cholangiocarcinoma. |
